Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a largest cohort study aimed to estimate the overall survival of patients been treated with regorafenib for metastatic colorectal cancer (mCRC) within the frame of a french compassionate program.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Oscar Lambret
• Collaborator: Bayer

Criteria

Inclusion criteria :

• Patient ≥ 18 years old

• With a colorectal cancer metastatic histologically proven

• Have met the criteria defined in the monograph ATU (Temporary Authorization for Use) validated by French Health Authorities and for which the request for access to treatment has been validated, that is in patients with mCRC as used in clinical practice for mCRC who have been previously treated with, or are not considered candidates for, available therapies.

• Patients who received at least one dose on REG

Exclusion criteria :

• Opposed to the study

• Patient does not meet the inclusion criteria

• Patient deprived of liberty or under guardianship